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The Ehlers-Danlos syndrome (EDS) is a heterogen�ous 
group of generalized connective tissue disorders, the 
major manifestations of which are skin fragility, skin 
hyperextensibility, andjoint hypermobility. The clini­
cal and molecular definition of more than ten types of 
EDS has, more than ever, emphasized the importance 
of correct diagnosis because the natural history and 
mode of inheritance dift"er among the types. Unfortu­
nately, much of the older literature does not dift"eren­
tiate among the types clearly, and in some instances the 
life-threatening complications ofEDS type IV may be 
cited as characteristic of the syndrome as a whole. 
Heterogeneity in EDS began to be appreciated about 
T he Ehlers-Danlos syndrome (EDS) is a heterogeneous group of generalized connective tissue disorders, the major manifestations of which are skin fragility, skin hyperextensibility, and joint hypermobility [1-3] (Table I). The clinical and molecular definition of 
more than ten types of EDS has, more than ever, emphasized the 
importance of correct diagnosis because the natural history and 
mode of inheritance differ among the types. Unfortunately, much 
of the older literature does not differentiate among the types clearly, 
and in some instances the life-threatening complications of EDS 
type IV may be cited as characteristic of the syndrome as a whole. 
Heterogeneity in EDS began to be appreciated about 30 years ago 
when the core of the modem classification was developed by Bara­
bas [4]. Since then it was extended by Beighton et al [5], and then 
amplified with the insights provided by biochemical and molecular 
genetic studies. Clinical studies were sufficient initially to distin­
guish five types of EDS; biochemical studies identified four addi­
tional types, EDS type VI [6],EDS type VII [7],EDS type IX [8], and 
EDS type X [9], whereas clinical criteria distinguished EDS type 
VIII [10]. 
PROGRESS IN UNDERSTANDING THE COMMON 
FORMS OF EDS (EDS TYPE I, EDS TYPE II, AND EDS 
TYPE III) HAS BEEN DISAPPOINTING 
Although their frequency is not well documented, Ehlers-Danlos 
syndrome types I, II, and III probably constitute the bulk of individ­
uals with EDS. These forms are all inherited in an autosomal domi­
nant fashion, all have marked joint mobility. They are distinguished 
by the extent and severity of skin involvement; individuals with 
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30 years ago when the core of the modern classification 
was developed by Barabas. Since then it was extended 
by Beighton et ai, and then amplified with the insights 
provided by biochemical and molecular genetic stud­
ies. Clinical studies were sufficient initially to distin­
guish five types ofEDS; biochemical studies identified 
four additional types, EDS type VI, EDS type VII, EDS 
type IX, and EDS type X, whereas clinical criteria dis­
tinguished EDS type vm. 
In the following sections, the clinical manifestations 
of the dift"erent forms ofEDS are summarized and the 
known biochemical and molecular genetic features are 
emphasized.] Invest DermatoI103:47S-52S, 1994 
EDS type I have very soft, markedly hyperextensible skin that 
bruises easily and heals with broad, thin scars (cigarerte-paper scars) . 
Scarring occurs typically on the forehead, under the chin, on the 
elbows and knees, and down the shins. Individuals with EDS type II 
have less striking involvement of skin but, nonetheless, have scars in 
the same characteristic distribution. Individuals with EDS type III 
may have few skin manifestations. 
The clues to the molecular basis of these cornmon forms ofEDS 
are few and far between. Recently cells from two individuals, who 
have joint hypermobility, hyperextensible skin, and mild aortic root 
dilatation, were found to secrete proal(l) trimers because they 
failed to make the proa2(1) chains of type I procollagen [11]. Al­
though these individuals fit the EDS type II clinical description 
with respect to skin and joint findings, the presence of aortic dila­
tion and the apparent recessive inheritance of the condition distin­
guishes a unique variant of EDS. Their clinical presentation also 
distinguishes them from a unique child with a form of osteogenesis 
imperfecta whose cells fail to produce proa2(I) chains. The bio­
chemical distinctions among these individuals need to be identified. 
Despite these intriguing clues, the molecular defects that underlie 
EDS types I,ll, and III are not known. Genetic linkage studies have 
excluded the candidate COLlAl and COLlA2 genes that encode 
the chains of type I procollagen, the most abundant protein in skin, 
as well as the COL2Al and COL3Al genes [12] . Biomechanical 
studies, suggestive of abnormal collagen in dermis [13], and electron 
microscopic studies of dermis that have demonstrated larger than 
normal collagen fibrils, frequent composite fibrils, and smaller than 
normal collagen fibers [14,15], nonetheless implicate collagen ab­
normalities in fibrillogenesis or fibril stabilization as potential ef­
fects of the underlying mutation. With the ability to scan rapidly 
well-spaced and highly informative loci in the genome, it would 
not be surprising if the gene locus (loci) that result in these disorders 
will be identified shortly and could include genes that encode pro-
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Table I. Clinical Features, Mode of Inheritance, and Biochemical Disorders in the Ehlers-Danlos Syndrome 
Type 
I: Gravis 
II: Mitis 
III: Familial hyper­
mobility 
IV: Arterial 
V: X-linked 
VI: Ocular 
VII: A and B Arthro­
chalasis multiplex 
congenita 
C: Dermatosparaxis 
VIII: Periodontal 
IX: X-linked cutis 
laxa; occipital 
horn syndrome 
X: Fibronectin defect 
Clinical Features 
Soft, velvety, hyperextensible skin; easy bruis­
ing; cigarette paper scars; hypermobile 
joints; varicose veins; prematurity 
Similar to EDS type I but less severe 
Soft skin, no scarring, marked large and small 
joint hypermobility 
Thin, translucent skin with visible veins; 
marked bruising; skin and joints have nor­
mal extensibility; arterial, bowel and uterine 
rupture. 
Similar to EDS type II 
Soft, velvety, hyperextensible skin; hypermo­
bile joints, scoliosis; ocular fragility and ker­
atoconus 
Congenital hip dislocation, joint hypermobil­
ity; soft skin with normal scarring 
Very soft, fragile, bruisable skin; 
Marked joint hypermobility 
Generalized periodontitis; skin similar to EDS 
type II 
Soft, extensible, lax skin; bladder diverticulae 
and rupture; short arms, limited pronation 
and supination, broad clavicles, occipital 
horns 
Similar to EDS type II 
teins (such as types V or XII collagens) that may have a role in 
fibrillogenesis. 
EHLERS-DANLOS SYNDROME TYPE IV RESULTS 
FROM AN ARRAY OF MUTATIONS IN THE COL3Al 
GENE THAT ENCODES THE CHAINS OF TYPE III 
PROCOLLAGEN 
EDS type IV, an uncommon form, the prevalence of which is 
variously estimated to be between 1: 105 and 1: 106[16], was recog­
nized as a distinct entity by Barabas [4] although Sack [17] and 
Gottron [18] had probably described the same entity a quarter cen­
tury earlier. Affected individuals have thin, translucent skin 
through which the venous pattern over the trunk, abdomen, and 
extremities is visible. As a rule joint hypermobility may be limited to 
the small joints of the hands and feet. A history of easy bruising is 
common. An acrogeric character to the hands and feet seen in some 
individuals has led to the idea that in the older European literature 
some individuals with acrogeria probably have EDS type IV. De­
spite a striking appearance in the adult, even in families in which 
offspring are known to be at 50% risk, it is often difficult to make 
the diagnosis on clinical grounds in children. Many individuals with 
EDS type IV are first thought to have disorders of coagulation 
because of the marked bruising. 
The major clinical complications of EDS type IV are arterial 
rupture, spontaneous rupture of the colon, and rupture of the gravid 
uterus [19,20]. Carotid-cavernous sinus fistula formation and re­
sultant unilateral exol'hthalmos is an uncommon complication of . 
EDS type IV [20-25]. Surgical repair or embolization has been 
attempted with success in some. Rupture of the distal colon. usuallr. 
in the sigmoid. is the most common of the bowel problems [20. 
Tissue friability and soiling of the peritoneal space are the major 
impediments to repair and rapid recovery. The degree of tissue 
friability differs among individuals and even in the same person 
difficulties with tissue repair appear to increase with aging. 
Uterine rupture is a rare complication ofEDS type IV in the last 
two months of pregnancy or during labor [19]. Uterine rupture 
generally is not recognized and leads to maternal and infant death 
because prompt sur�ical intervention is the only life-saving tech­
nique. In one series [191. almost 20% of the women withEDS type 
Inheritance 
AD 
AD 
(AR, rare) 
AD 
AD 
XLR 
AR 
AD 
AR 
AD 
XLR 
AR 
Molecular Defect 
Not known 
Not known 
COLlA2 null alleles 
Not known 
Mutations in the COL3Al gene that alter type 
III collagen synthesis, secretion, and structure 
Not known 
Lysyl hydroxylase deficiency due to mutations 
in the LOH gene 
A: COLlAl exon 6 skipping mutation that 
deletes N-proteinase cleavage site 
B: COLlAl exon 6 skipping mutation that 
deletes N-proteinase cleavage site 
C: Procollagen N-proteinase deficiency 
Not known 
Abnormal intracellular copper utilization with 
defect in Iysyl oxidase; probably allelic to 
Menkes syndrome 
Defect in fibronectin 
IV who became pregnant died as a result of pregnancy complica­
tions. Th.e absence of such complications in another series [26] 
makes it difficult to estimate the overall frequency of pregnancy­
related deaths. 
The life span of individuals with EDS type IV is generally shorter 
than that of their unaffected sibs with the mean age of death being in 
the early 30s for women and slightly older for men [201. Deaths in 
the third through the fifth decades are the rule with survival beyond 
50 years of age being apparently rare. 
EDS type IV results from heterozygosity for mutations in the 
COL3Al gene, so that the condition is inherited in an autosomal 
dominant fashion [27,28]. Although it has been proposed that auto­
somal recessive forms also exist [29,30], these must be rare. Asymp­
tomatic parental mosaicism for the mutation has been documented 
in three families and it is this, rather than recessive inheritance. that 
probably accounts for sibling recurrence in the absence of parental 
involvement [31- 33]. Because of the autosomal dominant mode of 
transmission, segregation studies using polymorphic restriction 
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Figure 1. Discrete mutations withiD the triple helix of the eOLlAI 
gene. A. location of point mutations that result in substitution of glycine 
residues in the triple helical domain of the al(lli) chain of type III collagen. 
The single letter code for amino acids is used. The mutation designated as 
G l36R indicates that glycine at position 135 of the triple helix is replaced by 
arginine. B,location of multi-exon deletions, and exon-skipping mutations 
in the COL3Al gene. 
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sites in the COL3Al gene, can be used to identify individuals with 
the affected allele and has the potential for use in prenatal diagnosis 
[28]. 
EDS type IV results from point mutations that produce substitu­
tion of glycine residues within the triple-helical domain, from 
exon-skipping mutations within the triple-helical domain, and 
from multi-exon deletions, all within the COL3Al gene. Almost a 
dozen discrete substitutions for glycine residues within the triple­
helix have been reported [31,32,34 -43] (see Fig 1). Exon-skipping 
events are almost as common as point mutations and include those 
that result in deletion of exons 16 f44], 20 [44-46], 25 [47], 27 [48], 
37 [49],41 [50,51], and 42 [44] within the triple helical dOIl}ain. 
Small genomic deletions entirely within an exon [52,53],' and 
multi-exon deletions [33,54,55] have also been identified. 
These mutations in the COL3Al gene all result in abnormalities 
in the structure, synthesis, or secretion of type III procollagen. As a 
result, the dermis and other tissues are often thin, collagen fiber 
bundles are small, and fibril diameters are either uniformly small or 
characterized by marked variation [56]. In some individuals, princi­
pally those with mutations near the carboxyl-terminal end of the 
triple helix, dermal fibroblasts have dilated rough endoplasmic re­
ticulum that contains the abnormal, poorly secreted type III procol­
lagen species [56,57]. In cell strains from other individuals [58], 
there is marked reduction in the extracellular accumulation of type 
III collagen and procollagen but little accumulation of abnormal 
procollagen within the cells . In these instances it is likely that mole­
cules that contain one or more mutant chains are rapidly degraded 
within the cell . 
EHLERS-DANLOS SYNDROME TYPE V, 
A DESIGNATION IN QUESTION 
EDS type V has been used to describe two families in which the 
inheritance of a phenotype clinically similar to EDS type II could be 
explained by X-linked recessive inheritance rather than variable 
expression of an autosomal dominant phenotype [59,60]. The origi­
nal investigators suggested that the disorder is rare; others [3] have 
suggested that this entity does not currently warrant a distinct des­
ignation. Until the gene is located, or the biochemical abnormality 
is found, this controversy cannot be resolved. 
EHLERS-DANLOS SYNDROME TYPE VI, AN 
AUTOSOMAL RECESSIVE CONDITION DUE TO 
DEFECTS IN LYSYL HYDROXYLASE 
EDS type VI, an autosomal recessive condition, was the first of the 
true disorders of collagen structure and biosynthesis to be identified 
[6,61]. The clinical features initially identified included soft, hyper­
extensible skin, joint hypermobility, scoliosis, ocular fragility, a 
marfanoid habitus that have more recently been supplemented by a 
propensity for bleeding from major vessels, the frequency of which 
remains uncertain, and motor delay [62]. The disorder is uncom­
mon and fewer than two dozen individuals have been identified 
[6,61-69]. 
The EDS type VI phenotype results from markedly decreased 
activity of the enzyme lysyl hydroxylase [6]. The variation in the 
enzyme activity in the cells from aff'ected individuals suggests that 
there is heterogeneity in the mutations in the gene. The recent 
isolation and characterization of the lysyl hydroxylase gene has 
facilitated mutation detection. In the first two families studied, ap­
parent homozygosity for mutations is probably consistent with pa­
rental consanguinity. In one [70] there was homozygosity for a stop 
codon at residue 319 (R319X), and in the other [71] there was an 
internal duplication of 180 bp within the coding sequence of the 
eDNA that apparently led to marked decrease in enzyme function. 
Prenatal diagnosis of EDS type VI by measurement of lysyl hy­
droxylase enzyme activity in amniotic fluid cells has been attempted 
in one family at risk. The birth of an unaff'ected but heterozygous 
infant was correctly predicted [65]. The presence of informative 
markers in the lysyl hydroxylase gene should facilitate diagnosis in 
families in which an affected child has been born. 
The post-translational hydroxylation of lysyl residues in types I 
and III collagen in sk in is reduced , but that of type II collagen in 
cartilage is normal or near normal. The residual enzyme appears to 
be almost normally efficient in the hydroxylation oflysyl residues in 
type IV collagen [72]. Diff'erential lysyl hydroxylation of collagen 
types in individuals with EDS type VI could be explained by difFer­
ent affinities of a single enzyme for the specific collagens or by the 
presence of collagen type-specific lysyl hydroxylases; only a single 
enzyme has been identified to date. 
Hydroxylation of lysyl residues in type 1 collagen is vital for the 
formation of normal crosslinks among collagen molecules [73] in 
that lysine-derived crosslinks are not as stable as those derived from 
hydroxylysine and do not mature as readily to the multi-component 
intermolecular links that stabilize molecular interactions at a larger 
scale. Presumably, the clinical phenotype results from the absence of 
the more complex crosslinks. 
EHLERS-DANLOS SYNDROME TYPE VII, NEW 
UNDERSTANDINGS OF THE PHENOTYPE 
EDS type VII designates disorders in which there are defects in the 
conversion of type I procollagen to collagen. 
EDS types VIlA and VIIB, also known as arthrochalasis multiplex 
congenita, are characterized by marked joint hypermobility, multi­
ple joint dislocations, and bilateral congenital hip dislocation that is 
often difficult to reduce, even with surgery. Mild to moderate short 
stature is seen in some individuals in whom mild midface hypoplasia 
is present. The prevalence of the condition is not known but it is 
probably uncommon. Although the m:yority of affected individuals 
described are sporadic in their families, there are two examples of 
autosomal dominant inheritance [74.75] and all the biochemical 
studies are compatible with the disorder being the result of domi­
nant mutations. 
The major complications of EDS type VIlA and VlIB are those 
which result from long-term instability of joints and failure to make 
a normal hip joint. Interestingly, bone fractures may be increased in 
some families with EDS type VIlA or VlIB. 
At first, EDS type VII was thought to result from abnormalities in 
the enzyme that cleaves the N-terminal propeptide extension from 
type I procollagen [7], probably because of the then recent discovery 
of the recessively inherited disorder, dermatosparaxis. in cattle [76]. 
However, further analysis of collagens synthesized by cells from 
several affected individuals demonstrated that the mutations in­
volve the cleavage sites of the substrate proal (I) and proa2(I) chains 
[77 -80]. In all patients with EDS type VIlA or VIIB in which the 
mutation has been characterized, the mRNA from the mutant allele 
lacks some or all of the sequence of exon 6. the domain that encodes 
the cleavage site for the N-proteinase. The genomic mutations are 
heterogeneous: in six, substitutions in the consensus splice sites 
surrounding exon 6 of the COLlA2 gene [81-85] are the cause, 
whereas in two others the mutations are in the COLIAI gene [86]. 
Deletion of all or part of the exon that encodes the N-terminal 
procollagen peptidase cleavage site has several effects on the mole­
cule: it deletes the site of cleavage in one chain, it throws into 
disarray the N-terminal cleavage site in molecules that incorporate 
the abnormal chain, and it removes a lysyl residue in the telopeptide 
extension that is frequently hydroxylated and involved in intermo­
lecular crosslinks. It is likely that the mutations alter crosslink for­
mation and fibrillogenesis and so decrease tensile strength of most 
tissues made up principally of type I collagen. 
Although a recessively inherited defect in procollagen conversion 
had been identified in cattle in 1971, the same condition was not 
identified in humans for more than 20 years [87-89]. The three 
children who have been identified are very similar and have fragile 
skin that bruises very easily, extremely soft, doughy skin, marked 
joint laxity with delayed motor milestones, blue sclerae, micro­
gnathia, large umbilical hernia, and mild hirsuitism. Intellectual 
development is normal . One child has had a central nervous system 
hemorrhage. 
Collagen fibrils in skin from the affected children have a charac­
teristic hieroglyphic appearance in cross-section and a ribbon-like 
appearance in longitudinal section. This reflects the presence of 
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little normal collagen, and an abundance of molecules in which the 
amino-terminal propeptide has been left in place, because the N­
proteinase that normally removes the peptide is missing, to disturb 
normal molecular interaction during fibril formation. 
EHLERS-DANLOS SYNDROME TYPE VIII 
EDS type VIII is characterized by bruising, soft, and hyperextensi­
ble skin, hypermobile joints, and periodontal disease [90,91] that is, 
affected individuals appear to have EDS type II but have marked 
periodontal disease. The disorder is inherited in an autosomal domi­
nant fashion, and loss of teeth, as a result of marked periodontal 
involvement, is common by the third decade. No biochemical de­
fects have been identified. 
EHLERS-DANLOS SYNDROME TYPE IX (OCCIPITAL 
HORN SYNDROME), A DEFECT IN COPPER 
METABOLISM 
EDS type IX is a rare X-linked recessive disorder characterized by 
lax and soft skin at birth, development of bladder diverticulae dur­
ing childhood, and the appearance of bony occipital horns during 
adolescence [92- 94]. Although the male subjects with this disorder 
are of normal height, skeletal deformities such as short humeral 
bones, partial radio-ulnar synostosis, and short broad clavicles are 
apparent on clinical and radiologic examination. Mild chronic diar­
rhea and orthostatic hypotension may be common. 
Like infants with the Menkes kinky hair syndrome, affected male 
subjects have a defect in distribution of intracellular copper to the 
apo-enzymes into which it is integrated [95-97]. The major mea­
sured effect of this defect is a decrease in the activity of the copper­
dependent enzyme, lysyl oxidase, which catalyzes the oxidation of 
lysyl residues in collagen and elastin to form crosslink precursors. 
Cells from these patients have a normal rate of copper uptake, but do 
not permit the normal effiux of copper bound to copper-enzymes 
and thus have very high intracellular levels. The recent isolation 
and characterization of the Menkes syndrome gene as a copper­
transporting ATPase [98-100] permitted testing in some of the 
families with X-linked cutis laxa. On the basis of those studies it 
appears that the disorders probably result from mutations in the 
same gene [101]. 
EHLERS-DANLOS SYNDROME TYPE X 
EDS type X is thought to be inherited in an autosomal recessive 
fashion and characterized by mild joint hypermobility and easy 
bruising. The disorder appears to result from an alteration in fibro­
nectin that interferes with normal platelet aggregation [102]. Only 
one family has been identified to date and the defect in fibronectin 
has never been identified. 
SUMMARY 
The clinical heterogeneity within the Ehlers-Danlos syndrome is 
due, in part, to mutations in several different genes. Thus type I 
collagen genes (COLIAl and COLtA2). the type III collagen gene 
(COL3Al).lysyl hydroxylase. procollagen N-protease, the copper 
transport gene, and fibronectin have each been implicated in differ­
ent forms ofEOS. For some forms ofEDS that historically acquired 
an individual designation (e.g., EOS type V and EOS type X) there 
must be some concern about the legitimacy in maintaining such 
distinctions and there is considerable need to pursue molecular ge­
netic studies in the known families. For the common forms ofEOS 
it has been a disappointing decade of relatively little search and 
unproductive searches when they have been completed. The new 
generation of molecular markers does, however. promise that if 
appropriate families can be identified then rapid progress can be 
made in identifying the candidate genes. These discoveries should 
further enlighten us about the manner in which the dermis and 
other connective tissues are assembled. 
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